Together with the Brain Health Mission, the EAN is excited to announce the launch of the Public Brain Health Day, on Monday, 23 June 2025, during the 11th EAN Congress in Helsinki.

Report from the 26th EAN Spring School 2025, held in the beautiful venue of Steinschaler Dörfl, Lower Austria, on 30 April – 4 May 2025.

The University of Cyprus in Nicosia was thrilled to host the highly anticipated 9th European Sleep Foundation (ESF) Sleep Medicine School from 31 March to 3 April 2025, endorsed by the EAN.

EAN Scientific Committee Chair, Gereon R. Fink, provides a look at various ongoing projects, including a variety of ways you can contribute to EAN scientific activities.

Welcome to the May 2025 edition of the President’s Corner, our article series in which the EAN President, Elena Moro, answers your questions!

Our papers of the month for May are two papers present findings from recent trials evaluating the efficacy and safety of tolebrutinib in patients with multiple sclerosis.

The Innovative Health Initiative (IHI) has just published draft topic texts for its upcoming Call 11, expected to launch officially in late June 2025.

The European Commission has released draft details for Horizon Europe’s 2025 Cluster 1 – Health calls, with official publication expected on 22 May 2025. These calls include several funding opportunities of high relevance to the neurology research community.

This month, the eanCampus is highlighting the topic of clinical neurophysiology, with several pieces of content freely accessible for non-members to enjoy.

Our summary of neurological news items the European Medicines Agency (EMA) monthly Human Medicines Newsletter.

The European Brain Council (EBC) has published its 2024 Annual Report, reflecting on and celebrating the organisation’s accomplishments in brain advocacy at national, European, and global levels in the previous calendar year.

The fourth EAN Science School took place in Salzburg, Austria on 21-25 March, bringing together 65 participants from 23 countries.

For the first time, guidelines for the management of urogenital symptoms reported by have been developed specifically for neurologists through a collaboration between the EAN, the International Neuro-Urology Society (INUS) and the European Federation of Autonomic Societies (EFAS).

The EAN was asked by a media outlet to provide comment on the possible role of creatine in the prevention of Alzheimer’s disease, the subject of much recent internet speculation.

Following an earlier decision by the EMA, the EU Commission has granted EU authorisation for Lecanemab to treat mild cognitive impairment in the early stages of Alzheimer’s disease.